In addition, case #26 may represent a good example of a patient that may be candidate to a target therapy with a BRAF inhibitor instead of conventional therapy as the neoplasm shows a dominant BRAF mutation in 83% of alleles. The gene discussed is BRAF; the disease is neoplasm.